A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulasta, Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2018
Price : $35 *
At a glance
- Drugs Lipegfilgrastim (Primary) ; Pegfilgrastim
- Indications Neutropenia
- Focus Registrational; Therapeutic Use
- Acronyms AVOID Neutropenia
- Sponsors Merckle
- 24 May 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2018 Planned End Date changed from 1 May 2018 to 24 Apr 2018.
- 06 Feb 2018 Planned End Date changed from 16 May 2018 to 1 May 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History